Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Pancreas ; 43(6): 886-90, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24717824

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the synergistic inhibitory effects of gemcitabine and losartan, angiotensin II type 1 (AT1) receptor blockers, on an orthotopic rat pancreatic cancer model. METHODS: The rat orthotopic pancreatic cancer model was prepared using DSL-6A/C cells, a rat ductal pancreatic adenocarcinoma cell line. The rats were treated with gemcitabine alone (100 mg/kg per week), losartan alone (100 mg/kg per day), or gemcitabine plus losartan. RESULTS: Survival was significantly improved by treatment with gemcitabine (89.6 ± 21.8 days) or losartan (76.9 ± 18.7 days) alone compared with that in the control group (59.6 ± 13.4 days; P < 0.05). Treatment with gemcitabine plus losartan further prolonged the survival time to 102.6 ± 16.5 days compared with that in the control group (P < 0.0001). Gemcitabine or losartan significantly and dose-dependently reduced the proliferation of DSL-6A/C cells in vitro. Both drugs inhibited pancreatic vascular endothelial growth factor expression compared with that in the control group (P < 0.05). CONCLUSIONS: The results of this study indicate that combined treatment with gemcitabine and losartan significantly improved the survival of rats with orthotopic pancreatic cancer by inhibiting vascular endothelial growth factor synthesis and suppressing cancer cell proliferation via AT1 receptor blockade. Thus, an AT1 receptor blocker in combination with gemcitabine might improve the clinical outcomes of patients with advanced pancreatic cancer.


Subject(s)
Adenocarcinoma/drug therapy , Angiotensin II Type 1 Receptor Blockers/pharmacology , Losartan/pharmacology , Pancreatic Neoplasms/drug therapy , Adenocarcinoma/blood supply , Adenocarcinoma/metabolism , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cell Line, Tumor , Cell Proliferation/drug effects , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Dose-Response Relationship, Drug , Immunohistochemistry , Losartan/administration & dosage , Male , Neoplasm Transplantation , Neovascularization, Pathologic/prevention & control , Pancreatic Neoplasms/blood supply , Pancreatic Neoplasms/metabolism , Rats, Inbred Lew , Receptor, Angiotensin, Type 1/metabolism , Survival Analysis , Treatment Outcome , Vascular Endothelial Growth Factor A/metabolism , Gemcitabine
2.
J Hepatobiliary Pancreat Sci ; 21(7): 473-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24339364

ABSTRACT

BACKGROUND: The most common postoperative complication after distal pancreatectomy (DP) is still postoperative pancreatic fistula (POPF), which is closely associated with other major complications and remains an unsolved problem. METHODS: This retrospective study included 47 consecutive patients who underwent a distal pancreatectomy with (DP-PG group, n = 21) or without (DP group, n = 26) duct-to-mucosa pancreaticogastrostomy from June 2010 to May 2012. Clinical data including POPF-related complications (POPF, fluid collection, intra-abdominal abscess, bleeding and delayed gastric emptying) as a primary endpoint were compared between the two groups. RESULTS: The frequencies of POPF-related complications as well as overall POPF and complications in the DP-PG group were lower than in the DP group (P = 0.037, P < 0.001, respectively). The 30 days morbidity after hospital discharge in the DP-PG group was less than in the DP group (P = 0.014). In both groups median hospital stay was similar. Although additional time needed for pancreaticogastrostomy was 35 (20-55) min, there was no difference in operative times. Patients in the DP group had a higher medical cost for hospitalization than the DP-PG group (P = 0.048). CONCLUSION: Pancreaticogastrostomy as an additional procedure following distal pancreatectomy was associated with a reduced rate of POPF-related complications that resulted in relatively lower medical cost for hospitalization.


Subject(s)
Gastrostomy/methods , Pancreas/surgery , Pancreatectomy/adverse effects , Pancreatic Fistula/complications , Adult , Aged , Anastomosis, Surgical , Digestive System Surgical Procedures/methods , Female , Humans , Male , Middle Aged , Pancreatic Neoplasms/surgery , Postoperative Complications/prevention & control , Retrospective Studies
4.
J Hepatobiliary Pancreat Sci ; 20(2): 206-13, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23179559

ABSTRACT

BACKGROUND: To investigate the behavior of activated pancreatic stellate cells (PSCs), which express alpha-smooth muscle actin (α-SMA), and pancreatic cancer cells in vivo, we examined the expression of α-SMA-positive myofibroblast-like cells in pancreatic cancer tissue after treatment with gemcitabine (GEM) using a Lewis orthotopic rat pancreatic cancer model. METHODS: The effect of GEM on DSL-6A/C1 cell proliferation was determined by cell counting method. The orthotopic pancreatic cancer animals were prepared with DSL-6A/C cells, and treated with GEM (100 mg/kg/weekly, for 3 weeks). At the end of treatment, α-SMA expression, fibrosis, transforming growth factor (TGF)-ß1 and vascular endothelial growth factor (VEGF) were evaluated by histopathological and Western blot analyses. RESULTS: DSL-6A/C1 cell proliferation was significantly reduced by co-culturing with GEM in vitro. Survival time of pancreatic cancer animals (59.6 ± 13.4 days) was significantly improved by treatment with GEM (89.6 ± 21.8 days; p = 0.0005). Alpha-SMA expression in pancreatic cancer tissue was significantly reduced after treatment with GEM (p = 0.03), however, there was no significant difference in Sirius-red expression. Expression of VEGF was significantly reduced by GEM treatment, but the expression of TGF-ß1 was not inhibited. CONCLUSION: GEM may suppress not only the tumor cell proliferation but also suppress PSCs activation through VEGF reduction.


Subject(s)
Actins/biosynthesis , Deoxycytidine/analogs & derivatives , Myofibroblasts/metabolism , Pancreatic Neoplasms/metabolism , Actins/drug effects , Animals , Antimetabolites, Antineoplastic/therapeutic use , Blotting, Western , Cell Proliferation , Deoxycytidine/therapeutic use , Immunohistochemistry , Male , Myofibroblasts/drug effects , Myofibroblasts/pathology , Neoplasms, Experimental , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Rats , Rats, Inbred Lew , Ribonucleotide Reductases/antagonists & inhibitors , Transforming Growth Factor beta1/biosynthesis , Transforming Growth Factor beta1/drug effects , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/biosynthesis , Gemcitabine
5.
J Surg Res ; 173(2): 299-308, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21195425

ABSTRACT

OBJECTIVE: Pancreatic cancer is a malignant neoplasm with poor prognosis that might be associated with defective immune function. We aimed to determine the influence on survival of circulating myeloid dendritic cells (c-m-DCs), circulating lymphoid DCs (c-l-DCs), and DCs within the tumor tissue in patients with pancreatic cancer. PATIENTS AND METHODS: Between December 2001 and June 2006, of a total of 110 patients with ductal adenocarcinoma of the pancreas, 42 underwent pancreatectomy, and 68 had unresectable disease. Numbers of c-m-DCs and c-l-DCs were assessed by flow cytometry, and DCs in the tumor tissue by immunohistochemical staining with anti-fascin mAb. RESULTS: The percentage of the c-m-DCs subset in pancreatic cancer patients was significantly lower than in healthy volunteers, and the similar finding was observed between patients who underwent surgical resection and non-resection. Patients with a high percentage of c-m-DCs or with many DCs accumulated in the cancer tissue survived longer than patients with a low percentage or low number in peripheral blood or the tumor, respectively. Moreover, there was a positive correlation between c-m-DCs within peripheral blood mononuclear cells and the number of DCs per field in the cancer tissue. CONCLUSIONS: Preoperative c-m-DCs levels in the PBMC of patients with pancreatic cancer and DCs counts in the cancer tissue can be a prognostic factor after surgical resection. Modulating the distribution of DCs may be an effective therapy in pancreatic cancer patients with a dismal prognosis.


Subject(s)
Adenocarcinoma/immunology , Dendritic Cells/pathology , Pancreatic Neoplasms/immunology , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Immunohistochemistry , Male , Middle Aged , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Prognosis , Survival Analysis
6.
Pancreas ; 41(3): 409-15, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22158072

ABSTRACT

OBJECTIVES: Regulatory T cells (Treg) can inhibit immune responses mediated by T cells. The aim of this study was to evaluate the prevalence of Treg in peripheral blood mononuclear cells from patients with pancreatic cancers in relation to their clinical outcomes. METHODS: Among a total of 100 patients with ductal adenocarcinoma of the pancreas, 40 underwent pancreatectomy and 60 had unresectable disease. Their peripheral blood mononuclear cells were evaluated to determine the proportion of CD4CD25 (FoxP3) T cells, as a percentage of the total CD4 cells, by flow cytometric analysis. RESULTS: The percentage of Treg in the patients with pancreatic cancer was significantly lower than that in the healthy volunteers (P = 0.048), and the patients who underwent surgical resection had lower Treg levels than those with unresectable disease (P = 0.040). Patients in the resected group with a higher percentage of Treg survived longer (P = 0.021). Treg in patients who remained disease free at postoperative 12 months significantly decreased compared to that of the postoperative period (P = 0.009). CONCLUSION: A relative increase in Treg may be related to immunosuppression and tumor progression in patients with pancreatic cancer. The immunological monitoring of Treg may be useful to predict the prognosis for patients with pancreatic cancer.


Subject(s)
CD4 Antigens/analysis , Carcinoma, Pancreatic Ductal/immunology , Forkhead Transcription Factors/analysis , Interleukin-2 Receptor alpha Subunit/analysis , Pancreatic Neoplasms/immunology , T-Lymphocytes, Regulatory/immunology , Adult , Aged , Aged, 80 and over , CD4 Lymphocyte Count , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Pancreatic Ductal/surgery , Case-Control Studies , Chi-Square Distribution , Female , Flow Cytometry , Humans , Japan , Kaplan-Meier Estimate , Male , Middle Aged , Pancreatectomy , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Time Factors , Treatment Outcome
7.
World J Gastroenterol ; 14(39): 6087-92, 2008 Oct 21.
Article in English | MEDLINE | ID: mdl-18932291

ABSTRACT

A 69-year-old man was diagnosed as having myasthenia gravis (MG) in September 2004, and treated with thymectomy and prednisolone. He was then diagnosed as having steroid-induced diabetes mellitus, and received sulfonylurea (SU) therapy in May 2005. An alpha-glucosidase inhibitor (alphaGI) was added in March 2006, resulting in good glycemic control. He experienced symptoms of abdominal distention, increased flatus, and constipation in October 2007, and was admitted into our hospital in late November with hematochezia. Plain abdominal radiography revealed small linear radiolucent clusters in the wall of the colon. Computed tomography (CT) showed intramural air in the sigmoid colon. Colonoscopy revealed multiple smooth surfaced hemispherical protrusions in the sigmoid colon. The diagnosis of pneumatosis cystoides intestinalis (PCI) was made on the basis of these findings. As the alphaGI voglibose was suspected as the cause of this patient's PCI, treatment was conservative, ceasing voglibose, with fasting and fluid supplementation. The patient progressed well, and was discharged 2 wk later. Recently, several reports of PCI associated with alphaGI therapy have been published, predominantly in Japan where alphaGIs are commonly used. If the use of alphaGIs becomes more widespread, we can expect more reports of this condition on a global scale. The possibility of PCI should be considered in diabetic patients complaining of gastrointestinal symptoms, and the gastrointestinal tract should be thoroughly investigated in these patients.


Subject(s)
Glycoside Hydrolase Inhibitors , Hypoglycemic Agents/adverse effects , Inositol/analogs & derivatives , Pneumatosis Cystoides Intestinalis/chemically induced , Pneumatosis Cystoides Intestinalis/diagnosis , Aged , Diabetes Mellitus/drug therapy , Humans , Hypoglycemic Agents/therapeutic use , Inositol/adverse effects , Inositol/therapeutic use , Male
8.
Nutr Cancer ; 60(5): 643-51, 2008.
Article in English | MEDLINE | ID: mdl-18791928

ABSTRACT

The aim of this study was to evaluate the effects of active hexose correlated compound (AHCC) intake on immune responses by investigating the number and function of circulating dendritic cells (DCs) in healthy volunteers. Twenty-one healthy volunteers were randomized to receive placebo or AHCC at 3.0 g/day for 4 wk. The number of circulating cluster of differentiation (CD)11c(+) DCs (DC1) and CD11c(-) DCs (DC2) were measured. Allogeneic mixed-leukocyte reaction (MLR) was performed. Natural killer (NK) cell activity and the proliferative response of T lymphocytes toward mitogen (phytohemagglutinin [PHA]) were measured. We also measured cytokine production stimulated by lipopolysaccharide [interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, tumor necrosis factor-alpha). The AHCC group (n = 10) after AHCC intake had a significantly higher number of total DCs compared to that at baseline and values from control subjects (n = 11). The number of DC1s in the AHCC group after intake was significantly higher than at baseline. DC2s in the AHCC group were significantly increased in comparison with controls. The MLR in the AHCC group was significantly increased compared to controls. No significant differences in PHA, NK cell activity, and cytokine production were found between groups. AHCC intake resulted in the increased number of DCs and function of DC1s, which have a role in specific immunity.


Subject(s)
Polysaccharides/immunology , Cytokines/immunology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Double-Blind Method , Female , Flow Cytometry/methods , Humans , Japan , Killer Cells, Natural/immunology , Male , Middle Aged , Reference Values , T-Lymphocytes/immunology
9.
Pancreas ; 37(2): 128-33, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18665071

ABSTRACT

OBJECTIVES: Pancreaticoduodenectomy (PD) is still associated with high morbidity. To reduce the frequency of postoperative complications, we have made revisions in perioperative managements of pancreaticoduodenectomy. METHODS: Subjects were 128 consecutive patients who underwent PD between January 2000 and August 2006. In June 2004, the following new departmental guidelines were introduced: (1) modified Kakita method of pancreaticojejunostomy, (2) omental wrapping, (3) early removal of closed-suction drain, and (4) restrictive use of pancreatic and biliary duct stenting. Operative mortality and morbidity between 77 patients managed conventionally (group A) and 51 patients since 2004 (group B) were compared. Risk factors for postoperative complications were determined. RESULTS: Postoperative morbidity in group B (39%) was significantly lower than in group A (64%; P = 0.019). Occurrence of grade B/C pancreatic fistula (PF) in group B (6%) was significantly lower than in group A (19%; P = 0.0376). Delayed gastric emptying was significantly reduced in group B relative to group A (23% vs 6%; P = 0.0133). Logistic regression analyses showed that the modified Kakita method was a negative independent factor for overall complications, PF, and delayed gastric emptying. CONCLUSIONS: The incidence of overall postoperative complications, grade B/C PF, and delayed gastric emptying after PD has been reduced because of the introduction of a new guideline.


Subject(s)
Pancreaticoduodenectomy/methods , Postoperative Complications/prevention & control , Aged , Aged, 80 and over , Female , Gastric Emptying , Humans , Japan , Male , Middle Aged , Morbidity , Pancreatic Fistula/etiology , Pancreatic Fistula/prevention & control , Pancreaticoduodenectomy/adverse effects , Postoperative Complications/etiology , Time Factors
13.
J Gastroenterol ; 41(12): 1178-85, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17287897

ABSTRACT

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are major causes of gastric mucosal lesions. In Japan, histamine-2 receptor antagonists are frequently prescribed, but the literature regarding their efficacy is limited. In this study, we compare the effects of famotidine and rebamipide on NSAID-associated gastric mucosal lesions using upper gastrointestinal endoscopy. METHODS: This study examined 112 patients taking NSAIDs for either gastric hemorrhage or erosion. Before treatment, the patients were assessed by endoscopy. Using blind randomization, patients were divided into two groups: group F (famotidine, 20 mg/day) and group R (rebamipide, 300 mg/day). Efficacy was examined 4 weeks later using endoscopy. RESULTS: After treatment, the Lanza score decreased significantly in group F (P < 0.001) but not in group R (P = 0.478). The change in the Lanza score in group F was significantly greater (P = 0.002) than that in group R. CONCLUSIONS: Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions.


Subject(s)
Alanine/analogs & derivatives , Anti-Ulcer Agents/therapeutic use , Famotidine/therapeutic use , Gastric Mucosa/pathology , Quinolones/therapeutic use , Stomach Ulcer/drug therapy , Adult , Aged , Alanine/administration & dosage , Alanine/therapeutic use , Anti-Ulcer Agents/administration & dosage , Endoscopy, Gastrointestinal , Famotidine/administration & dosage , Female , Humans , Male , Middle Aged , Peptic Ulcer Hemorrhage/drug therapy , Quinolones/administration & dosage
14.
Clin Pediatr Endocrinol ; 14(1): 35-7, 2005.
Article in English | MEDLINE | ID: mdl-24790308

ABSTRACT

We report the case of a 21-yr-old female with Turner syndrome associated with cerebral hemorrhage (CH). She was transferred to our hospital for loss of consciousness and was diagnosed with right putaminal hemorrhage. Following surgical removal of the hematoma, she regained consciousness, and her left hemiplegia gradually improved after surgery. Angiography revealed absence of vascular abnormality of the cerebral artery, aorta, and renal arteries. Hypertension was noted on arrival at the hospital and persisted after surgery. A slight hypertensive change was observed in her retinas. Plasma renin activity was elevated (20 ng/ml/h) and renovascular hypertension was suspected. In this patient, CH was suspected to have occurred due to hypertension. This case emphasizes the necessity to carefully monitor the blood pressure in Turner syndrome cases, even during childhood.

15.
Biochem Biophys Res Commun ; 309(2): 324-30, 2003 Sep 19.
Article in English | MEDLINE | ID: mdl-12951053

ABSTRACT

Mouse embryonic stem (ES) cells are clonal cell lines derived from the inner cell mass of developing blastocysts and have multi-lineage differentiation ability. We previously reported that ES cells can be made to differentiate into hepatocytes possessing high metabolic activities by transfection of hepatocyte nuclear factor-3beta (HNF-3beta). In the present study, we investigated the expression of hepatobiliary organic anion transporters and bilirubin uridine diphosphate glucuronosyltransferase (ugt1a1) in undifferentiated and differentiating HNF-3beta-transfected ES (HNF-3beta-ES) cells. The expression of organic anion transporting polypeptide 1 (oatp1), multidrug resistance-associated protein 1 (mrp1), mrp2, mrp3, and ugt1a1 was not seen in the undifferentiated HNF-3beta-ES cells by RT-PCR, whereas all were expressed in differentiating HNF-3beta-ES cells. Protein expression for oatp1, mrp1, mrp2, mrp3, and ugt1a1 was also observed in the differentiating HNF-3beta-ES cells by Western blotting. An immunofluorescence examination revealed that oatp1 was co-located with desmoplakin, a marker for the basolateral (sinusoidal) membrane, and mrp2 was co-localized with CD26, a marker for the apical (canalicular) membrane, though they were both expressed throughout most of the cell membranes.


Subject(s)
DNA-Binding Proteins/metabolism , Glucuronosyltransferase/biosynthesis , Hepatocytes/metabolism , Multidrug Resistance-Associated Proteins/biosynthesis , Nuclear Proteins/metabolism , Organic Anion Transporters/biosynthesis , Stem Cells/metabolism , Transcription Factors , Animals , Cell Differentiation , Cell Line , DNA-Binding Proteins/genetics , Gene Expression Regulation, Developmental , Glucuronosyltransferase/genetics , Hepatocyte Nuclear Factor 3-beta , Hepatocytes/cytology , Mice/embryology , Mice/genetics , Multidrug Resistance-Associated Proteins/genetics , Nuclear Proteins/genetics , Organic Anion Transporters/genetics , Stem Cells/cytology , Transfection/methods
SELECTION OF CITATIONS
SEARCH DETAIL